WuXi AppTec doubled after the Pentagon tried to blacklist it

A federal judge blocked the Pentagon's designation of WuXi AppTec as a Chinese military company on 7 August, granting a preliminary injunction that Reuters says found the listing likely 'arbitrary and capricious.' The stock had already been sliding since the 8 June designation; now it's up roughly 100% from those lows, per Bloomberg, because WuXi makes the drug-product ingredients behind much of the West's GLP-1 supply and investors have decided no amount of national-security paperwork changes that this quarter. UBS and BlackRock remain shareholders of record. The injunction buys time, not certainty: the BIOSECURE Act still looms, and a five-year wind-down clause for existing contracts pushes the real deadline into the 2030s. Merck, Novo Nordisk and every other Western pharma client leaning on WuXi's Chinese factories just got a reprieve, not an answer.